论文部分内容阅读
目的 研究肾综合征出血热 (HFRS)Vero传代细胞疫苗。方法 将HFRS双价沙鼠肾细胞灭活疫苗的生产疫苗株Z10 (Ⅰ型 )、Z3 7(Ⅱ型 )适应到Vero细胞上进行连续传代 ,并用不同代次的Vero细胞适应株制备Vero传代细胞疫苗。结果 Z10 、Z3 7株感染Vero细胞后第 1代即可达到较高病毒滴度 ,并且在Vero细胞中持续传代适应 ,病毒滴度分别维持在 6.2 5～ 6.75和 6.5 0～ 7.0 0logTCID50 /ml之间 ,较为稳定。用不同代次的Vero细胞适应株制备而成的HFRSVero细胞灭活疫苗抗原效价和疫苗的病毒滴度有较大提高 ,反向间接血凝效价从Z10 Cp1Vero细胞疫苗的阴性上升到Z10 Cp10 Vero细胞疫苗的 1∶64 ,从Z3 7Cp1Vero细胞疫苗的 1∶2上升到Z3 7Cp10 Vero细胞疫苗的 1∶64 ;疫苗病毒滴度(logTCID50 /ml)从Z10 Cp1Vero细胞疫苗的 4.2 5上升到Z10 Cp10 Vero细胞疫苗的 6.5 0 ,从Z3 7Cp1Vero细胞疫苗的 6.2 5上升到Z3 7Cp10 Vero细胞疫苗的 7.5 0。疫苗在抗原量和病毒滴度上基本符合中国生物制品的要求。结论 HFRSVero传代细胞疫苗的生产 ,疫苗株在Vero细胞中的连续传代适应起关键性作用。
Objective To study Vero passage cell vaccine against hemorrhagic fever with renal syndrome (HFRS). Methods Vaccine strains Z10 (type Ⅰ) and type Z3 7 (type Ⅱ) were inoculated on Vero cells for continuous passage and the Vero cell line was used to prepare Vero passage cells vaccine. Results The first generation of Z10 and Z3 7 infected Vero cells could reach higher virus titer and continue to be passaged in Vero cells with virus titers maintained at 6.25-6.75 and 6.5 0-7.0 0logTCID50 / ml, respectively Between, more stable. HFRSVero cell inactivated vaccine antigen titer prepared with different generations of Vero cell adapted strains and the vaccine virus titer has greatly increased, reverse indirect coagulation titer rose from the negative of Z10 Cp1Vero cell vaccine to Z10 Cp10 Vero cell vaccine rose from 1: 2 of the Z3 7Cp1 Vera cell vaccine to 1:64 of the Z3 7Cp10 Vero cell vaccine; the vaccine virus titer (logTCID50 / ml) increased from 4.2 5 of the Z10 Cp1 Vera cell vaccine to the Z10 Cp10 The 6.5 0 for the Vero cell vaccine increased from 6.2 5 for the Z3 7Cp1 Vera cell vaccine to 7.5 0 for the Z3 7Cp10 Vero cell vaccine. Vaccine in antigen and virus titer basically meet the requirements of China’s biological products. Conclusions The production of HFRSVero passaged cell vaccines and the continuous passage of vaccine strains in Vero cells play a key role.